Welcome to our dedicated page for INTEST SEC filings (Ticker: INTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INTEST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INTEST's regulatory disclosures and financial reporting.
INTEST CORP Division President – Electronic Test, Joseph Richard McManus Jr., reported routine equity compensation changes and related tax withholding. He received 2,535 restricted shares and 2,535 performance-based restricted shares of Common Stock that were granted under the company’s 2023 Stock Incentive Plan and vest over multiple years, including installments starting on March 16, 2027 and potential vesting in March 2029 based on performance.
He also received an employee stock option covering 4,284 shares of Common Stock at an exercise price of $14.47 per share, expiring in 2036, which vests in four equal annual installments beginning on March 16, 2027. To cover tax obligations on the vesting of restricted stock on March 17, 2026, 296 shares of Common Stock were withheld at a price of $14.46 per share. After these transactions, he directly owns 35,693 Common shares and holds several option awards with exercise prices between $7.74 and $16.06 expiring between 2031 and 2035.
inTEST Corp CFO Duncan Gilmour reported equity compensation awards, not open-market trading. He received an employee stock option for 9,736 shares of common stock at an exercise price of $14.47 per share, expiring in 2036, which will vest in four equal annual installments starting March 16, 2027.
He was also granted 5,760 time-based restricted shares that vest in four equal annual installments beginning on March 16, 2027, plus 5,760 performance-based restricted shares that may vest in March 2029 if specified performance goals are met, with a maximum of 8,640 shares eligible to vest at peak performance.
Following these awards, Gilmour holds 67,954 shares of common stock directly and 200 shares indirectly through his spouse, along with multiple previously granted stock options with exercise prices between $7.74 and $16.80 expiring from 2031 through 2035.
inTEST Corp President & CEO Richard N. Grant Jr. reported new equity awards and a small share sale. He received 13,822 restricted shares that vest in four equal annual installments starting on March 16, 2027, and 13,822 performance-based restricted shares that may vest in March 2029 depending on performance, with a maximum of 20,733 shares vesting at above-target results. He was also granted an option for 23,365 shares of common stock at an exercise price of $14.47, vesting over four years beginning on March 16, 2027.
On March 18, 2026, Grant sold 1,636 common shares at a weighted average price of $14.279 per share to satisfy tax withholding obligations tied to restricted stock vesting, under a Rule 10b5-1 trading plan adopted on December 8, 2023. After this sale, he directly owns 212,730 common shares. He also continues to hold multiple option grants with exercise prices ranging from $7.74 to $16.06 and expiration dates between 2031 and 2035.
Maginnis Gerald J. reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Gerald J. Maginnis received an award of 12,000 shares of Common Stock on March 16, 2026. The grant carried a price of $0.0000 per share, indicating a share-based award rather than a market purchase. After this transaction, he directly holds 96,057 shares.
DEWS JOSEPH W IV reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Joseph W. Dews IV received an equity award of 12,000 shares of Common Stock on March 16, 2026. The shares were granted at no cash cost per share as compensation, not bought on the open market. After this award, he directly holds 130,250 shares in total.
ABRAMS STEVEN J reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Steven J. Abrams received a grant of 12,000 shares of Common Stock on March 16, 2026, at no stated purchase price. After this award, he holds 21,000 shares directly. An additional 87,000 shares are held indirectly through the Steven J. Abrams Revocable Trust.
INTEST CORP director Jeffrey A. Beck received an award of 12,000 shares of common stock. The grant was recorded at no cash cost per share and represents a compensation-related acquisition rather than an open-market purchase. After this grant, Beck directly holds 79,500 shares of INTT common stock.
INTEST CORP reported a proposed sale of Common Stock on a Form 144. The filing lists a broker-dealer (Citigroup Global Markets, Inc.) and a Restricted Stock Aware Vesting entry showing 6,460 shares. It also discloses two recent sales by Grant Richard N. Jr: 1,097 shares on 03/09/2026 for $14,618.51 and 1,397 shares on 03/11/2026 for $19,786.97.
inTEST Corporation provides an overview of its business for the year ended December 31, 2025, highlighting a diversified test and process technology portfolio across semiconductor, Auto/EV, Defense/Aerospace, Industrial, Life Sciences and Safety/Security markets. About 68% of 2025 revenue, or $77.9 million, came from markets outside semiconductor, reflecting progress on its VISION 2030 diversification strategy.
The company completed the acquisition of Alfamation S.p.A. for a total purchase price of $21.9 million, expanding automotive and specialty consumer electronics test capabilities and adding a related-party facility lease in Italy. It also consolidated Videology’s Netherlands operations into Massachusetts, incurring $0.8 million in severance charges and expecting about $0.3 million of remaining lease costs.
Backlog grew to $53.9 million at December 31, 2025, up from $39.5 million a year earlier, and inTEST ended the year with 407 employees. The filing also describes segment structures, key products, competitive landscape, acquisition and growth risks, supply chain exposure, AI and cybersecurity risks, and details of its $3.8 million debt with M&T Bank and related covenant waivers.
INTEST CORP President & CEO Richard N. Grant Jr. reported open-market sales of company common stock that were used to cover taxes on vesting restricted stock. He sold 1,397 shares at $14.1639 per share and 1,097 shares at $13.3259 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2023. After these transactions, he holds 186,722 common shares directly and maintains multiple employee stock option awards, including options expiring between 2031 and 2035 with exercise prices ranging from $7.7400 to $16.0600.